Anil Bhandari, MD
Clinical Cardiac Electrophysiology · Los Angeles, CANPI 1669466439
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $52,846 of the $79,180 with a category attached, or 66.7%. Abbott accounts for 63.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $19,368 and has fallen 51.2% since, to $9,459 in 2025.
Across 111 payments — averaging $713.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$50K
- Johnson & Johnson$17K
- Sanofi-aventis U.S. LLC$9K
- Janssen Research & Development, LLC$1K
- Biosense Webster, Inc.$444
- Medtronic$207
- plus $843 from 5 others
Across 16 payments — averaging $2742.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medical Device Business Services, Inc.$23K
- Janssen Research & Development, LLC$21K
What the payments were for
- Consulting fees$52,84667%
- Speaking & faculty fees$21,85028%
- Travel & lodging$1,7102%
- Food & beverage$2,7754%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 54 | $49,864 |
| Johnson & Johnson | 17 | $17,122 |
| Sanofi-aventis U.S. LLC | 4 | $9,476 |
| Janssen Research & Development, LLC | 9 | $1,223 |
| Biosense Webster, Inc. | 15 | $444 |
| Medtronic | 1 | $207 |
| Medical Device Business Services, Inc. | 1 | $200 |
| Kestra Medical Technology Services, Inc. | 2 | $177 |
| Cvrx, Inc. | 1 | $169 |
| Biotronik Inc. | 3 | $151 |
| Boston Scientific | 4 | $146 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE$25,413
- XARELTO$16,836
- MULTAQ$9,476
- COOL PATH$5,344
- Therapy Ablation Catheter$3,919
- TactiCath Quartz CFA Catheter$3,175
- TACTICATH$475
- Azure$207
- Lasso$200
- Quadra Assura CRT Defibrillator$177
- Barostim Neo System$169
- CardioMEMS HF System$165
- CARDIOMEMS$160
- Assure WCD$114
How this compares
$79,180 in reported general payments places this provider in the 75th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 188 | $247,497 |
| XareltoRivaroxaban | 174 | $196,188 |
| MultaqDronedarone Hcl | 41 | $65,235 |
| EntrestoSacubitril/Valsartan | 43 | $32,873 |
| JardianceEmpagliflozin | 28 | $30,251 |
| Dofetilide | 79 | $19,598 |
| Flecainide Acetate | 100 | $5,388 |
| Amiodarone Hcl | 171 | $3,896 |
| Metoprolol Succinate | 184 | $2,800 |
| Rosuvastatin Calcium | 78 | $1,741 |
| Ranolazine ErRanolazine | 23 | $1,576 |
| Nebivolol Hcl | 29 | $1,541 |
| Diltiazem Hcl | 23 | $993 |
| Potassium Chloride | 50 | $844 |
| SotalolSotalol Hcl | 51 | $834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $17,122 | $196,188174 claims |
| Sanofi-aventis U.S. LLCMultaq | $9,476 | $65,23541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in Los Angeles
- Leslie SaxonLos Angeles$1.1M
- Rahul DoshiLos Angeles$469K
- Koonlawee NademaneeLos Angeles$446K
- Ivan HoLos Angeles$294K
- Eric BuchLos Angeles$213K
- Carlos MaciasLos Angeles$160K
- Olujimi AjijolaLos Angeles$159K
- Justin HayaseLos Angeles$100K
- Omar YasinLos Angeles$87K
- Shephal DoshiSanta Monica$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.